Morgan Stanley Maintains Equal-Weight on Genmab, Lowers Price Target to $56
Genmab (CPSE:GMAB) Stock Could Be 47% Undervalued As Epcoritamab Approvals Expand
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Is Genmab (CPSE:GMAB) Fully Priced After Holding 2026 Guidance Steady?
What Is Genmab (CPSE:GMAB) Signaling With New Cancer Trial Data?
Genmab (GMAB) Q3 2026 Earnings Call Transcript
Moody’s lifts Genmab outlook to positive on pipeline progress, debt reduction
Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ...
What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
Genmab A/S (GMAB) Q3 2026 Earnings Call Transcript
Genmab Q3 EPS $5.51 Beats $3.59 Estimate, Sales $1.187B Miss $1.194B Estimate
Genmab Affirms FY2026 Sales Guidance of $4.325B-$4.525B vs $4.472B Est
Genmab Announces Financial Results for the Nine Months of 2026
Genmab Q3 2026 Earnings Call Transcript
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
Morgan Stanley Maintains Equal-Weight on Genmab, Raises Price Target to $57
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.